Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
INTERVENTIONAL
2006-06-30
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Desmopressin (DDAVP), already used for patients with von Willebrand syndrome, could reduce bleeding and transfusion requirements in these patients when administered ev (0.3 mg/kg) in 20-30 minutes postoperatively.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Desmopressin as Treatment for Postoperative Bleeding After Cardiac Surgery
NCT00885924
Transfusion Reduction in High-Bleeding-Risk Cardiac Surgery With Desmopressin
NCT07012837
DDAVP Effect by TEG6 in Cardiac Surgery
NCT07179991
Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies
NCT06622187
Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery
NCT01994330
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Desmopressin (DDAVP)
Desmopressin (DDAVP)
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Desmopressin (DDAVP)
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* excessive bleeding
Exclusion Criteria
* not signing written consent
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Università Vita-Salute San Raffaele
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Giovanni Landoni, MD
Role: STUDY_DIRECTOR
Università Vita-Salute San Raffaele, Milano, Italia e Istituto Scientifico San Raffaele, Milano, Italia.
Giuseppe Crescenzi, MD
Role: PRINCIPAL_INVESTIGATOR
Università Vita-Salute San Raffaele, Milano, Italia e Istituto Scientifico San Raffaele, Milano, Italia.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istituto Ospedaliero Fondazione Poliambulanza
Brescia, , Italy
Università Vita-Salute San Raffaele, Milano, Italia e Istituto Scientifico San Raffaele, Milano, Italia
Milan, , Italy
Istituto Policlinico S.Donato
Milan, , Italy
Azienda Ospedaliera Universitaria Pisana
Pisa, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Crescenzi G, Landoni G, Biondi-Zoccai G, Pappalardo F, Nuzzi M, Bignami E, Fochi O, Maj G, Calabro MG, Ranucci M, Zangrillo A. Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. Anesthesiology. 2008 Dec;109(6):1063-76. doi: 10.1097/ALN.0b013e31818db18b.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DS/URC/ER/mm 151/DG
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.